PMID- 33239910
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201127
IS  - 1179-1314 (Print)
IS  - 1179-1314 (Electronic)
IS  - 1179-1314 (Linking)
VI  - 12
DP  - 2020
TI  - Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging 
      Clinical Data.
PG  - 251-258
LID - 10.2147/BCTT.S219436 [doi]
AB  - Hormone receptor positive, human epidermal growth factor receptor 2 negative 
      (HR+/HER2 negative) breast cancer accounts for over 70% of all breast cancers. 
      There has been much advancement in the treatment of HR+/HER2 negative metastatic 
      breast cancer (MBC), in particular the development of more tailored and targeted 
      therapies. Recently, greater understanding of the role of phosphatidylinositol 
      3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in breast cancer 
      has led to the development of PI3K inhibitors, which have proven to be effective 
      in the treatment of HR+/HER2 negative MBC. In this review, we will discuss the 
      role of the PI3K/AKT/mTOR pathway in breast cancer and therapies that have been 
      developed to inhibit PI3K. We will discuss in detail the development of PI3K 
      inhibitor alpelisib, indications for use in HR+/HER2 negative MBC, safety and 
      tolerability and the future direction of this therapy in the treatment of breast 
      cancer.
CI  - (c) 2020 Armaghani and Han.
FAU - Armaghani, Avan J
AU  - Armaghani AJ
AD  - Department of Breast Oncology, Moffitt McKinley Outpatient Center, H. Lee Moffitt 
      Cancer Center and Research Institute, Tampa, FL 33612, USA.
FAU - Han, Hyo Sook
AU  - Han HS
AD  - Department of Breast Oncology, Moffitt McKinley Outpatient Center, H. Lee Moffitt 
      Cancer Center and Research Institute, Tampa, FL 33612, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201118
PL  - New Zealand
TA  - Breast Cancer (Dove Med Press)
JT  - Breast cancer (Dove Medical Press)
JID - 101591856
PMC - PMC7680678
OTO - NOTNLM
OT  - PI3K
OT  - PIK3CA
OT  - alpelisib
COIS- Dr Hyo Sook Han reports personal fees from Lilly, research funding to institution 
      from Arvinas, Abbvie, BMS, Daiichi, G1 therapeutics, GSK, Horizon, Maker 
      therapeutics, Novartis, Pfizer, Prescient, Seattle Genetics, Zymeworks, grants 
      from Department of Defense, outside the submitted work. The authors report no 
      other conflicts of interest in this work.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
PMCR- 2020/11/18
CRDT- 2020/11/26 05:44
PHST- 2020/08/06 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/11/26 05:44 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
PHST- 2020/11/18 00:00 [pmc-release]
AID - 219436 [pii]
AID - 10.2147/BCTT.S219436 [doi]
PST - epublish
SO  - Breast Cancer (Dove Med Press). 2020 Nov 18;12:251-258. doi: 
      10.2147/BCTT.S219436. eCollection 2020.